Obesity Study

Results From Amgen’s Phase 2 Obesity Study of Monthly Maritide Presented at the American Diabetes Association 85th Scientific Sessions

Amgen shared a post on X:

“Results from Amgen’s Phase 2 obesity study being presented during an expert-led symposium at the American Diabetes Association 85th Scientific Sessions.

The data evaluated MariTide in people living with obesity, with and without Type 2 diabetes.

Learn more.”

Proceed to the video attached to the post. 

More posts featuring AMGEN.